Seminars in Nuclear Medicine
Volume 33, Issue 1 , Pages 2-13, January 2003

Radiopharmaceuticals for single-photon emission computed tomography brain imaging1

  • Hank F. Kung

      Affiliations

    • Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA
    • Department of Pharmacology, University of Pennsylvania, Philadelphia, PA, USA
    • Corresponding Author InformationAddress reprint requests to Hank F. Kung, Department of Radiology, University of Pennsylvania, Philadelphia PA 19104.
    • ,
  • Mei-Ping Kung

      Affiliations

    • Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA
    • Department of Pharmacology, University of Pennsylvania, Philadelphia, PA, USA
    • ,
  • Seok Rye Choi

      Affiliations

    • Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA
    • Department of Pharmacology, University of Pennsylvania, Philadelphia, PA, USA

Article Outline

In the past 10 years, significant progress on the development of new brain-imaging agents for single-photon emission computed tomography has been made. Most of the new radiopharmaceuticals are designed to bind specific neurotransmitter receptor or transporter sites in the central nervous system. Most of the site-specific brain radiopharmaceuticals are labeled with 123I. Results from imaging of benzodiazepine (γ-aminobutyric acid) receptors by 123Iiomazenil are useful in identifying epileptic seizure foci and changes of this receptor in psychiatric disorders. Imaging of dopamine D2/D3 receptors ([123I]iodobenzamide and [123I]epidepride) and transporters [123I]CIT (2-beta-carboxymethoxy-3-beta(4-iodophenyl)tropane) and [123I]FP-β-CIT (N-propyl-2-beta-carboxymethoxy-3-beta(4-iodophenyl)-nortropane has proven to be a simple but powerful tool for differential diagnosis of Parkinson's and other neurodegenerative diseases. A 99mTc-labeled agent, [99mTc]TRODAT (technetium, 2-[[2-[[[3-(4-chlorophenyl)-8-methyl-8-azabicyclo [3, 2, 1]oct-2-yl]methyl](2-mercaptoethyl)amino]ethyl]amino] ethanethiolato(3-)]oxo-[1R-(exo-exo)]-), for imaging dopamine transporters in the brain has been successfully applied in the diagnosis of Parkinson's disease. Despite the fact that 123I radiopharmaceuticals have been widely used in Japan and in Europe, clinical application of 123I-labeled brain radiopharmaceuticals in the United States is limited because of the difficulties in supplying such agents. Development of 99mTc agents will likely extend the application of site-specific brain radiopharmaceuticals for routine applications in aiding the diagnosis and monitoring treatments of various neurologic and psychiatric disorders.

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Jurisson SS, Lydon JD. Potential technetium small molecule radiopharmaceuticals. Chem Rev. 1999;99:2205–2218
  2. Steigman J, Eckelman WC. In: The Chemistry of Technetium in Medicine. Washington, DC: National Academy; 1992;p. 180
  3. Hom RK, Katzenellenbogen JA. Technetium-99m-labeled receptor-specific small-molecule radiopharmaceuticals: Recent developments and encouraging results. Nucl Med Biol. 1997;24:485–498
  4. Johannsen B, Pietzsch H-J. Development of technetium-99m-based CNS receptor ligands: Have there been any advances?. Eur J Nucl Med. 2002;29:263–275
  5. Camargo EE. Brain SPECT in neurology and psychiatry. J Nucl Med. 2001;42:611–623
  6. Garcia EV, Faber TL, Galt JR, et al. Advances in nuclear emission PET and SPECT imaging. IEEE Eng Med Biol Mag. 2000;19:21–33
  7. Eckelman WC. Radiolabeled muscarinic radioligands for in vivo studies. Nucl Med Biol. 2001;28:485–491
  8. Eckelman WC. Sensitivity of new radiopharmaceuticals. Nucl Med Biol. 1998;25:169–173
  9. Laruelle M. The role of model-based methods in the development of single scan techniques. Nucl Med Biol. 2000;27:637–642
  10. Catafau AM. Brain SPECT in clinical practice. Part I: Perfusion. J Nucl Med. 2001;42:259–271
  11. Bremner JD, Baldwin R, Horti A, et al. Quantitation of benzodiazepine receptor binding with PET [11C]iomazenil and SPECT [123Iiomazenil: Preliminary results of a direct comparison in healthy human subjects. Psychiatry Res. 1999;91:79–91
  12. Matheja P, Ludemann P, Kuwert T, et al. Disturbed benzodiazepine receptor function at the onset of temporal lobe epilepsy—lomanzenilbinding in de-novo TLE. J Neurol. 2001;248:585–591
  13. Venz S, Hierholzer J, Cordes M, et al. Quantitative estimation of I-123-iomazenil receptor binding in temporal lobe epilepsies using two SPECT acquisitions—Comparison with the regional cerebral blood flow and a compartment model. Nuklearmedizin. 1998;37:49–56
  14. (review) Brinkmann BH, O'Brien TJ, Mullan BP, et al. Subtraction ictal SPECT coregistered to MRI for seizure focus localization in partial epilepsy. In: Mayo Clin Proc. 75:2000;p. 615–624
  15. Nakagawara J, Sperling B, Lassen NA. Incomplete brain infarction of reperfused cortex may be quantitated with iomazenil. Stroke. 1997;28:124–132
  16. Nakabeppu Y, Nakajo M, Naruo T, et al. I-123 iomazenil SPECT in patients with mental disorders. Ann Nucl Med. 1997;11:339–344
  17. Abi-Dargham A, Krystal JH, Anjilvel S, et al. Alterations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT and [123I]iomazenil. Am J Psychiatry. 1998;155:1550–1555
  18. Pinborg LH, Videbaek C, Hasselbalch SG, et al. Benzodiazepine receptor quantification in Huntington's disease with [(123)I]omazenil and SPECT. J Neurol Neurosurg Psychiatry. 2001;70:657–661
  19. Neve KA, Neve RL. In: The Dopamine Receptors. Totowa, NJ: Humana Press; 1997;
  20. Verhoeff NP. Radiotracer imaging of dopaminergic transmission in neuropsychiatric disorders. Psychopharmacology. 1999;147:217–249
  21. Volkow ND, Fowler JS, Gatley SJ, et al. PET evaluation of the dopamine system of the human brain. J Nucl Med. 1996;37:1242–1253
  22. Mukherjee J, Yang ZY, Brown T, et al. Preliminary assessment of extrastriatal dopamine D-2 receptor binding in the rodent and nonhuman primate brains using the high affinity radioligand, 18F-fallypride. Nucl Med Biol. 1999;26:519–527
  23. Kung HF, Kasliwal R, Pan S, et al. Dopamine D2 receptor imaging radiopharmaceuticals: Synthesis, radiolabeling and in vitro binding of R(+)- and S(−)-3-iodo-2-hydroxy-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)-methyl]-benzamide. J Med Chem. 1988;31:1039–1043
  24. Torizuka K, Mizuno Y, Kubo A, et al. [Phase 2 clinical study of 123I-IBF, a dopamine D2 receptor imaging agent, to evaluate clinical efficacy and safety in Parkinson's disease and Parkinson syndromes]. Kaku Igaku. 1999;36:845–864
  25. Yonekura Y, Sadato N, Tsuchida T, et al. [Phase 1 clinical study of 123I-IBF, a new radioligand for evaluating Dopamine D2 receptor with SPECT (II): Pharmacokinetics study and quantification in the brain]. Kaku Igaku. 1999;36:155–168
  26. Ichise M, Ballinger JR, Vines D, et al. Simplified quantification and reproducibility studies of dopamine D2-receptor binding with iodine-123-IBF SPECT in healthy subjects. J Nucl Med. 1997;38:31–37
  27. Ryding E, Tuninger E, Ohlsson T, et al. Dopamine D2-receptor density in humans as assessed with SPET and the new high-affinity ligand 123I-NCQ298: A pilot study. Nucl Med Commun. 1998;19:263–270
  28. Kuikka JT, Akerman KK, Hiltunen J, et al. Striatal and extrastriatal imaging of dopamine D2 receptors in the living human brain with [123I]epidepride single-photon emission tomography. Eur J Nucl Med. 1997;24:483–487
  29. Stephenson CM, Bigliani V, Jones HM, et al. Striatal and extrastriatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. [(123)I]-epidepride single photon emission tomography (SPET) study. Br J Psychiatry. 2000;177:408–415
  30. Varrone A, Fujita M, Verhoeff NP, et al. Test-retest reproducibility of extrastriatal dopamine D2 receptor imaging with [123I]epidepride SPECT in humans. J Nucl Med. 2000;41:1343–1351
  31. Pinborg LH, Videbaek C, Knudsen GM, et al. Dopamine D(2) receptor quantification in extrastriatal brain regions using [(123)I]epidepride with bolus/infusion. Synapse. 2000;36:322–329
  32. Mach RH, Nader MA, Ehrenkaufer RLE, et al. Comparison of two F-18 labeled benzamide derivatives that bind reversibly to dopamine D2 receptors: In vitro binding studies and positron emission tomography. Synapse. 1996;24:322–333
  33. Mukherjee J, Yang Z-Y, Das MK, et al. Fluorinated benzamide neuroleptics. III. Development of (S)-N-[1-ally12-pyrrolidinyl)methyl[5-(3-[18F]fluoropropyl)-2,3-dimethoxy-benzamide as an improved dopamine D2 receptor tracer. Nucl Med Biol. 1995;22:283–296
  34. Högberg TA, Rämsby S, Ögren S-O, et al. New selective dopamine D2 antagonists as antipsychotic agents. Pharmacological, chemical, structural and theoretical considerations. Acta Pharm Suec. 1987;24:289–328
  35. Staffen W, Hondl N, Trinka E, et al. SPET investigations in extrapyramidal diseases using specific ligands. Nucl Med Commun. 1997;18:159–163
  36. Schwarz J, Oertel WH, Tatsch K. Iodine-123-iodobenzamide binding in parkinsonism: Reduction by dopamine agonists but not L-Dopa. J Nucl Med. 1996;37:1112–1115
  37. Eisensehr I, Wetter TC, Linke R, et al. Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic restless legs syndrome. Neurology. 2001;57:1307–1309
  38. Brücke T, Wenger S, Asenbaum S, et al. Dopamine D2 receptor imaging and measurement with SPECT. Adv Neurol. 1993;60:494–500
  39. Schwarz J, Tatsch K, Gasser T, et al. [123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy. Mov Disord. 1997;12:898–902
  40. Tissingh G, Booij J, Winogrodzka A, et al. IBZM- and CIT-SPECT of the dopaminergic system in parkinsonism. J Neural Transm Suppl. 1997;50:31–37
  41. Videbaek C, Toska K, Friberg L, et al. In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography. J Cereb Blood Flow Metab. 2001;21:92–97
  42. Barnas C, Quiner S, Tauscher J, et al. In vivo (123)I IBZM SPECT imaging of striatal dopamine 2 receptor occupancy in schizophrenic patients. Psychopharmacology. 2001;157:236–242
  43. Kasper S, Tauscher J, Kufferle B, et al. Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol—A 123I-IBZM SPECT study. Psychopharmacology. 1998;136:367–373
  44. Staedt J, Stoppe G, Kogler A, et al. [123I]IBZM SPET analysis of dopamine D2 receptor occupancy in narcoleptic patients in the course of treatment. Biol Psychiatry. 1996;39:107–111
  45. Pilowsky LS, O'Connell P, Davies N, et al. In vivo effects on striatal dopamine D2 receptor binding by the novel atypical antipsychotic drug sertindole—A 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology. 1997;130:152–158
  46. Tauscher J, Kufferle B, Asenbaum S, et al. In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology. 1999;141:175–181
  47. Dresel S, Mager T, Rossmuller B, et al. In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: An iodine-123 iodobenzamide single-photon emission tomography study. Eur J Nucl Med. 1999;26:862–868
  48. Kessler RM, Mason NS, Votaw JR, et al. Visualization of extrastriatal dopamine D2 receptors in the human brain. Eur J Pharmacol. 1992;223:105–107
  49. Fujita M, Verhoeff NP, Varrone A, et al. Imaging extrastriatal dopamine D(2) receptor occupancy by endogenous dopamine in healthy humans. Eur J Pharmacol. 2000;387:179–188
  50. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review. J Cereb Blood Flow Metab. 2000;20:423–451
  51. Laruelle M. The role of endogenous sensitization in the pathophysiology of schizophrenia: Implications from recent brain imaging studies. Brain Res Brain Res Rev. 2000;31:371–384
  52. Booij J, Korn P, Linszen DH, et al. Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide single-photon emission tomography. Eur J Nucl Med. 1997;24:674–677
  53. Abi-Dargham A, Gil R, Krystal J, et al. Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort. Am J Psychiatry. 1998;155:761–767
  54. Acton PD, Pilowky LS, Costa DC, et al. Multivariate cluster analysis of dynamic iodine-123 iodobenzamide SPET dopamine D2 receptor images in schizophrenia. Eur J Nucl Med. 1997;24:111–118
  55. Frost JJ, Rosier AJ, Reich SG, et al. Positron emission tomographic imaging of the dopamine transporter with [11C]-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol. 1993;34:423–431
  56. Schonbachler RD, Gucker PM, Arigoni M, et al. PET imaging of dopamine transporters in the human brain using [11C]-beta-CPPIT, a cocaine derivative lacking the 2beta-ester function. Nucl Med Biol. 2002;29:19–27
  57. Marek K, Innis R, van Dyck C, et al. [123I]Beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology. 2001;57:2089–2094
  58. Carroll FI, Scheffel U, Dannals RF, et al. Development of imaging agents for the dopamine transporter. Med Res Dev. 1995;15:419–444
  59. Abi-Dargham A, Gandelman MS, DeErausquin GA, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J Nucl Med. 1996;37:1129–1133
  60. Booij J, Tissingh G, Winogrodzka A, et al. Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease. Eur J Nucl Med. 1997;24:68–71
  61. Goodman MM, Kung M-P, Kabalka GW, et al. Synthesis and characterization of radioiodinated N-(3-iodopropen-1-yl)-2β-carbomethoxy-3β-(4-chlorophenyl)tropanes: Potential dopamine reuptake site imaging agents. J Med Chem. 1994;37:1535–1542
  62. Mozley PD, Kim HJ, Gur RC, et al. [I-123]IPT SPECT imaging of CNS dopamine transporters: Non-linear effects of normal aging on striatal uptake values. J Nucl Med. 1996;37:1965–1970
  63. Tatsch K, Schwarz J, Mozley PD, et al. Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomography. Eur J Nucl Med. 1997;24:415–421
  64. Chalon S, Garreau L, Emond P, et al. Pharmacological characterization of (E)-N-(3-iodoprop-2-enyl)-2-carbomethoxy-3-(4′-methylphenyl)nortropane as a selective and potent inhibitor of the neuronal dopamine transporter. J Pharmacol Exp Ther. 1999;291:648–654
  65. Fischman AJ, Bonab AA, Babich JW, et al. Rapid detection of Parkinson's disease by SPECT with altropane: A selective ligand for dopamine transporters. Synapse. 1998;29:128–141
  66. Madras BK, Meltzer PC, Liang AY, et al. Altropane, a SPECT or PET imaging probe for dopamine neurons: I. Dopamine transporter binding in primate brain. Synapse. 1998;29:93–104
  67. Kung HF. Development of Tc-99m labeled tropanes: TRODAT-1, as a dopamine transport imaging agent. Nucl Med Biol. 2001;28:505–508
  68. Davison A, Jones AG, Orvig C, et al. A new class of oxotechnetium (+5) chelate complexes containing a TcON2S2 core. Inorg Chem. 1981;20:1629–1632
  69. Meegalla SK, Plössl K, Kung M-P, et al. Specificity of diastereomers of [99mTc]TRODAT-1 as dopamine transporter imaging agents. J Med Chem. 1998;41:428–436
  70. Meegalla SK, Plössl K, Kung M-P, et al. Synthesis and characterization to Tc-99m labeled tropanes as dopamine transporter imaging agents. J Med Chem. 1997;40:9–17
  71. Meltzer PC, Blundell P, Jones AG, et al. A technetium-99m SPECT imaging agent which targets the dopamine transporter in primate brain. J Med Chem. 1997;40:1835–1844
  72. Tamagnan GD, Baldwin R, Kula NS, et al. Cyclopentadienyltricar-bonylrheniumbenzazepines: Synthesis and binding affinity. Bioorg Med Chem Lett. 2000;10:1113–1115
  73. Meegalla SK, Plössl K, Kung M-P, et al. First example of a Tc-99m complex as a dopamine transport imaging agent. J Am Chem Soc. 1995;117:11037–11038
  74. Meegalla SK, Plössl K, Kung M-P, et al. Tc-99m labeled tropanes as dopamine transporter imaging agents. Bioconjung Chem. 1996;7:421–429
  75. Mozley P, Stubbs J, Plössl K, et al. Biodistribution and dosimetry of TRODAT-1: A technetium-99m tropane for imaging dopamine transporters. J Nucl Med. 1998;39:2069–2076
  76. Mozley PD, Acton PD, Baraclough ED, et al. Effects of age on dopamine transportes in healthy humans. J Nucl Med. 1999;40:1812–1817
  77. Mozley PD, Schneider JS, Acton PD, et al. Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers. J Nucl Med. 2000;41:584–589
  78. Acton PD, Mozley PD. Single photon emission tomography imaging in parkinson an disorders: A review. Behav Neurol. 2000;12:11–27
  79. Acton PD, Meyer PT, Mozley PD, et al. Simplified quantifications of dopamine transporters in humans using 99mTc]TRODAT-1 and single photon emission tomography. Eur J Nucl Med. 2000;27:1714–1718
  80. Wong DF, Yung B, Dannals RF, et al. In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN35,428. Synapse. 1993;15:130–142
  81. Poyot T, Conde F, Gregoire MC, et al. Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: Comparison with 6-[18F]fluoro-l-dopa. J Cereb Blood Flow Metab. 2001;21:782–792
  82. Van Dick CH, Seibyl JP, Malison RT, et al. Age-related decline in dopamine transporter binding in human striatum with [123I]β-CIT SPECT. J Nucl Med. 1995;36:1175–1181
  83. (letter) Tissingh G, Bergmans P, Winogrodzka A, et al. Nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med. 1997;38:1271–1272
  84. Booij J, Bergmans P, Winogrodzka A, et al. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease. Synapse. 2001;39:101–108
  85. Mozley PD, Stubbs JB, Kim H-J, et al. Dosimetry of an iodine-123-labeled tropane to image dopamine transporters. J Nucl Med. 1996;37:151–159
  86. Fischman AJ, Bonab AA, Babich JW, et al. [(11)C, (127)I]Altropane: A highly selective ligand for PET imaging of dopamine transporter sites. Synapse. 2001;39:332–342
  87. Huang WS, Lin SZ, Lin JC, et al. Evaluation of early-stage Parkinson's disease with 99mTc-TRODAT-1 imaging. J Nucl Med. 2001;42:1303–1308
  88. Tzen KY, Lu CS, Yen TC, et al. Differential diagnosis of Parkinson's disease and vascular parkinsonism by (99m)Tc-TRODAT-1. J Nucl Med. 2001;42:408–413
  89. Kao PF, Tzen KY, Yen TC, et al. The optimal imaging time for [99Tcm]TRODAT-1/SPET in normal subjects and patients with Parkinson's disease. Nucl Med Commun. 2001;22:151–154
  90. Seibyl JP. Single-photon emission computed tomography of the dopamine transporter in parkinsonism. J Neuroimaging. 1999;9:223–228
  91. review Brooks DJ. Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease. J Neurol. 2000;247(suppl 2):II11–II18
  92. Yen T-C, Lu C-S, Tzen K-Y, et al. Decreased dopamine transposrter binding in Machado-Joseph disease. J Nucl Med. 2000;41:994–998
  93. Yen TC, Tzen KY, Chen MC, et al. Dopamine transporter concentration is reduced in asymptomatic Machado-Joseph disease gene carriers. J Nucl Med. 2002;43:153–159
  94. Dresel S, Krause J, Krause K-H, et al. Attention deficit hyperactivity disorder: Binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. Eur J Nucl Med. 2000;27:1518–1524
  95. Krause K-H, Dresel SH, Krause J, et al. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett. 2000;285:107–110
  96. Kilbourn MR. In vivo binding of [18F]GBF 13119 to the brain dopamine uptake system. Life Sci. 1988;42:1347–1353
  97. Tedroff J, Aquilonius SM, Hartvig P, et al. Monoamine re-uptake sites in the human brain evaluated in vivo by means of 11C-nomifensine and positron emission tomography: The effects of age and Parkinson's disease. Acta Neurol Scand. 1988;77:192–201
  98. Volkow ND, Fowler JS, Wang GJ. Imaging studies on the role of dopamine in cocaine reinforcement and adiction in humans. J Psychopharmacol. 1999;13:337–345
  99. Volkow ND, Wang G-J, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci. 2001;21:RC121
  100. Volkow ND, Wang GJ, Fischman MW, et al. Effects of route of adminstration on cocaine induced dopamine transporter blockade in the human brain. Life Sci. 2000;67:1507–1515
  101. Fowler JS, Volkow ND, Wang GJ, et al. [(11)]Cocaine: PET studies of cocaine pharmacokinetics, dopamine transporter availability and dopamine transporter occupancy. Nucl Med Biol. 2001;28:561–572
  102. Malison RT, Best SE, van Dyck CH, et al. Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I] beta-CIT SPECT. Am J Psychiatry. 1998;155:832–834
  103. Malison RT, Best SE, Wallace EA, et al. Euphorigenic doses of cocaine reduce [123I]beta-CIT SPECT measures of dopamine transporter availability in human cocaine addicts. Psychopharmacology. 1995;122:358–362
  104. Frazer A. Antidepressants. J Clin Psychiatry. 1997;6:9–25
  105. Staley JK, Malison RT, Innis RB. Imaging of the serotonergic system: Interactions of neuroanatomical and functional abnormalities of depression. Biol Psychiatry. 1998;44:534–549
  106. Meltzer CC, Smith G, DeKosky ST, et al. Serotonin in aging, late-life depression, and Alzheimer's disease: The emerging role of functional imaging. Neuropsychopharmacology. 1998;18:407–430
  107. Szabo Z, Kao PF, Scheffel U, et al. Positron emission tomography imaging of serotonin transporters in the human brain using [11C](+)McN5652. Synapse. 1995;20:37–43
  108. Elfing B, Bjornholm B, Ebert B, et al. Binding characteristics of selective serotonin reuptake inhibitors with relation to emission tomography studies. Synapse. 2001;41:203–211
  109. Szabo Z, Scheffel U, Mathews WB, et al. Kinetic analysis of [11C]McN5652: A serotonin transporter radioligand. J Cereb Blood Flow Metab. 1999;19:967–981
  110. Parsey RV, Kegeles LS, Hwang DR, et al. In vivo quantification of brain serotonin transporters in humans using [11C]McN 5652. J Nucl Med. 2000;41:1465–1477
  111. Ricaurte GA, McCann UD, Szabo Z, et al. Toxicodynamics and long-term toxicity of the recreational drug, 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’). Toxicol Lett. 2000;112–113:143–146
  112. McCann UD, Szabo Z, Scheffel U, et al. Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings. Lancet. 1998;352:1433–1437
  113. Biegon A, Mathis CA, Hanrahan SM, et al. [125I]5-Iodo-6-nitroquipazine: A potent and selective ligand for the 5-hydroxytryptamine uptake complex II in vivo studies in rats. Brain Res. 1993;619:236–246
  114. Mathis CA, Taylor SE, Biegon A, et al. [125I]5-Iodo-6-nitroquipazine: A potent and selective ligand for the 5-hydroxytryptamine uptake complex I in vitro studies. Brain Res. 1993;619:229–235
  115. Jagust WJ, Eberling JL, Biegon A, et al. Iodine-123-5-iodo-6-nitroquipazine: SPECT radiotracer to image the serotonin transporter. J Nucl Med. 1996;37:1207–1214
  116. Fujita M, Takatoku K, Matoba Y, et al. Differential kinetics of [123I]beta-CIT binding to dopamine and serotonin transporters. Eur J Nucl Med. 1996;23:431–436
  117. Kuikka JT, Bergstrom KA, Ahonen A, et al. Comparison of iodine-123 labelled 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and 2 beta-carbomethoxy-3 beta-(4-iodophenyl)-N-(3-fluoropropyl) nortropane for imaging of the dopamine transporter in the living human brain. Eur J Nucl Med. 1995;22:356–360
  118. Tiihonen J, Kuikka JT, Bergstrom KA, et al. Single-photon emission tomography imaging of monoamine transporters in impulsive violent behaviour. Eur J Nucl Med. 1997;24:1253–1260
  119. Pirker W, Asenbaum S, Kasper S, et al. β-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. J Neural Transm Gen Sect. 1995;100:247–256
  120. Tauscher J, Pirker W, de Zwaan M, et al. In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment. Eur Neuropsychopharmacol. 1999;9:177–179
  121. Malison RT, Price LH, Berman R, et al. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry. 1998;44:1090–1098
  122. Willeit M, Praschak-Rieder N, Neumeister A, et al. [123I]-β-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder. Biol Psychiatry. 2000;47:482–489
  123. Laruelle M, Abi-Dargham A, van Dyck C, et al. Dopamine and serotonin transporters in patients with schizophrenia: An imaging, study with, [123I]β-CIT. Biol Psychiatry. 2000;47:371–379
  124. Bergstrom KA, Halldin C, Hall H, et al. In vitro and in vivo characterisation of nor-beta-CIT: A potential radioligand for visualisation of the serotonin transporter in the brain. Eur J Nucl Med. 1997;24:596–601
  125. Blough BE, Abraham P, Mills AC, et al. 3 Beta-(4-ethyl-3-iodophenyl)nortropane-2 beta-carboxylic acid methyl ester as a high-affinity selective ligand for the serotonin transporter. J Med Chem. 1997;40:3861–3864
  126. Hiltunen J, Akerman KK, Kuikka JT, et al. Iodine-123 labeled nor-beta-CIT as a potential tracer for serotonin transporter imaging in the human brain with single-photon emission tomography. Eur J Nucl Med. 1998;25:19–23
  127. Ferris RM, Brieaddy L, Mehta N, et al. Pharmacological properties of 403U76, a new chemical class of 5-hydroxytryptamine-and noradrenaline-reuptake inhibitor. J Pharm Pharmacol. 1995;47:775–781
  128. Oya S, Kung MP, Acton PD, et al. A new single-photon emission computed tomography imaging agent for serotonin transporters: [123I] IDAM, 5-iodo-2-((2-((dimethylamino)methyl)phenyl)thio)benzyl alcohol. J Med Chem. 1999;42:333–335
  129. Zhuang ZP, Choi SR, Hou C, et al. A novel serotonin transporter ligand: (5-iodo-2-(2-dimethylaminomethylphenoxy)Benzyl alcohol (ODAM). Nucl Med Biol. 2000;27:169–175
  130. Acton PD, Kung MP, Mu M, et al. Single-photon emission tomography imaging of serotonin transporters in the non-human primate brain with the selective radioligand [123I]IDAM. Eur J Nucl Med. 1999;26:854–861
  131. Kung MP, Hou C, Oya S, et al. Characterization of [123I]IDAM as a novel single-photon emission tomography tracer for serotonin transporters. Eur J Nucl Med. 1999;26:844–853
  132. Acton PD, Choi SR, Hou C, et al. Quantification of serotonin transporters in nonhuman primates using [123I]ADAM and SPECT. J Nucl Med. 2001;42:1556–1562
  133. Choi SR, Hou C, Oya S, et al. Selective in vitro and in vivo binding of [125I]ADAM to serotonin transporters in rat brain. Synapse. 2000;38:403–412
  134. Oya S, Choi SR, Hou C, et al. 2-((2-((dimethylamino) methyl)phenyl)thio)-5-Iodophenylamine, (ADAM): An improved serotonin transporter ligand. Nucl Med Biol. 2000;27:249–254
  135. Kauppinen T, Bergström K, Heikman P, et al. Biodistribution and radiation dosimetry of [123I] ADAM in healthy human subjects: Preliminary results. Eur J Nucl Med. 2003;30:132–136
  136. Wilson AA, Ginovart N, Schmidt M, et al. Novel radiotracers for imaging the serotonin transporter by positron emission tomography: Synthesis, radiosynthesis, and in vitro and ex vivo evaluation of 11C-labeled 2-(phenylthio)araalkylamines. J Med Chem. 2000;43:3103–3110
  137. Houle S, Ginovart N, Hussey D, et al. Imaging the serotonin transporter with positron emission tomography: Inital human studies with [11C]DAPP and [11C]DASB. Eur J Nucl Med. 2000;27:1719–1722
  138. Ginovart N, Wilson AA, Meyer JH, et al. Positron emission tomography quantification of [11C]DASB binding to the human serotonin transporter: Modeling strategies-Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [11C]DASB PET imaging study. J Cereb Blood Flow Metab. 2001;21:1342–1353
  139. Meyer JH, Kruger S, Wilson AA, et al. Lower dopamine transporter binding potential in striatum during depression. Neuroreport. 2001;12:4121–4125
  140. Meyer JH, Wilson AA, Ginovart N, et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [11C]DASB PET imaging study. Am J Psychiatry. 2001;158:1843–1849
  141. Frazer A. Serotonergic and noradrenergic reuptake inhibitors: Prediction of clinical effects from in vitro potencies. J Clin Psychiatry. 2001;62:16–23
  142. Eckelman WC, Reba RC, Rzeszotarski WJ, et al. External imaging of cerebral muscarinic acetylcholine receptors. Science. 1984;223:291–293
  143. Eckelman WC. Designing a molecular probe for muscarinic acetylcholine-receptor (mAChR) imaging. J Nucl Med. 1995;36:S5–S7
  144. (review) Sihver W, Nordberg A, Langstrom B, et al. Development of ligands for in vivo imaging of cerebral nicotinic receptors. Behav Brain Res. 2000;113:143–157
  145. Musachio JL, Villemagne VL, Scheffel UA, et al. Synthesis of an I-123 analog of A-85380 and preliminary, SPECT imaging of nicotinic receptors in baboon. Nucl Med Biol. 1999;26:201–207
  146. Kulak JM, Sum J, Musachio JL, et al. 5-Iodo-A-85380 binds to alpha-conotoxin MII-sensitive nicotinic acetylcholine receptors (nAChRs) as well as alpha4beta2* subtypes. J Neurochem. 2002;81:403–406
  147. Kassiou M, Eberl S, Meikle SR, et al. In vivo imaging of nicotinic receptor upregulation following chronic(-)-nicotine treatment in baboon using SPECT. Nucl Med Biol. 2001;28:165–175

1 This work was partially supported by Grants EB00358 and EB-00360 from the National Institutes of Health.

PII: S0001-2998(03)80002-8

doi:10.1053/snuc.2003.127296

Seminars in Nuclear Medicine
Volume 33, Issue 1 , Pages 2-13, January 2003

Article Tools